65,437 trials
Pain · Education · Virtual Reality
Primary: Change From Baseline in Pain Beliefs Questionnaire Score After VR Intervention Approximately 45 Minutes Later — .35; .95; .45; .55 score on a scale — p=.137
Neurofibromatosis 2 · Meningioma
Primary: Radiographic Response Rate for Target Meningioma — 1 target meningiomas
Chronic Low Back Pain
Primary: Difference Between Arms in Least Squared (LS) Mean Change in Oswestry Disability Index (ODI) — -25.3; -4.4 units on a scale — p=<0.001
Full-thickness Rotator Cuff Tear
Primary: Mean Visual Analog Scale — 3.5; 5.9; 3.1; 5.2 units on a scale — p=.006
Blood Pressure
Primary: Change From Baseline in Flow Mediated Dilation After 24 Hour Ischemic Conditioning With Blood Pressure Cuff — 6.6 percentage of baseline
Bariatric Surgery · Obesity
Primary: Change in Pharmacokinetics as Assessed by Cmax (Max Concentration) — 5.3; -6.7 ng/ml
Hypertension
Primary: Blood Pressure (Systolic) at 180 Days — 131; 131 mmHg — p=<0.001
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Diabetes
Primary: Body Weight — -4.0; .8; -.9 kg
Small Cell Lung Cancer (SCLC)
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 4.8…
PNH
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 3; 2; 1; 0 Participants
Oral Malodor
Primary: Reduction in Malodor as Measured by Organoleptic Score — 3.58; 3.60; 3.63; 3.65 score on a scale — p=<0.00001
Type 2 Diabetes Mellitus
Primary: Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6 — 0.09; 0.21 percent change — p=0.5494
Schizophrenia
Primary: Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score — 61.8; 61.0; -10.5; -8.8 score on a scale — p=0.0434
Medullary Thyroid Carcinoma · Multiple Endocrine Neoplasia Type 2A · Multiple Endocrine Neoplasia Type 2B
Primary: Maximum Tolerated Dose (MTD) — 100 mg/m^2/day